These catheters are used for guidewire support to aid in lesion crossing and for guidewire exchanges.
Support catheters are used by physicians in approximately 50% of PVIs, mainly in below-the-knee and complex interventions. Lesions with calcium present can be challenging to cross with an interventional guidewire and frequently need innovative tools for vessel preparation and treatment.
CSI expects to launch the newly acquired catheters as its new ViperCross line in the first half of its fiscal year ending on 30 June next year.
Furthermore, WavePoint will develop a speciality catheter portfolio for treating chronic total occlusions (CTO) and complex percutaneous coronary intervention (PCI) procedures for CSI, as part of this deal.
CTOs signify a substantial and growing segment of PCIs and often result in poor patient outcomes.
The company anticipates these speciality catheters to be commercially available in its fiscal year ending 30 June 2023.
CSI chairman, president and CEO Scott Ward said: “With the acquisition of these peripheral support catheters, CSI will soon offer a complete portfolio of products for the treatment of peripheral artery disease, including atherectomy, balloon catheters, guidewires, support catheters and embolic protection.
“In coronary, the successful development of a portfolio of CTO products will expand our existing offering of coronary support products.
“Together, these new products advance our ability to help physicians improve outcomes for patients undergoing complex peripheral and coronary interventions.”
This month, CSI announced that the first patients in the US were treated with its distal embolic protection filter, the WIRION Embolic Protection System.
WIRION is used for capturing thrombus and debris linked to all types of PVI procedures, including atherectomy.